Advertisement
Home »

Positive Efficacy & Safety Results of Novel BlyS/APRIL Inhibitor in Rheumatoid Arthritis

Jan 07, 2024

REFERENCES & ADDITIONAL READING

Wang L, et al. Telitacicept, a human recombinant fusion protein targeting and neutralizing B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL), in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate (MTX): A randomized, double-blind, Phase 3 study. L20, ACR Convergence 2023, November 10-15, 2023, San Diego, USA.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement